Work

Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia

Year: 2020

Type: article

Source: Leukemia

DOI: 10.1038/s41375-020-0764-6

Authors: Christopher A. Eide, Stephen E. Kurtz, Andy Kaempf, Nicola Long, Anupriya Agarwal, Cristina E. Tognon, Motomi Mori, Brian J. Druker, Bill H. Chang, Alexey V. Danilov, Jeffrey W. Tyner

Institutions: Howard Hughes Medical Institute, Oregon Health & Science University, OHSU Knight Cancer Institute, Portland State University

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute

Awards: G1581679921, G2034128388, Mechanisms and targeting of inflammatory cytokine-driven expansion and progression in AML, Architecture and Trajectory of Acquired Resistance to Therapy in AML, OHSU Knight Cancer Institute

OpenAlex ID: W3008538713

FWCI: 2.563

Cites: 53

Cited by: 22

Related to: 10